<DOC>
	<DOCNO>NCT02116530</DOCNO>
	<brief_summary>This randomized phase III trial study antiemetic therapy olanzapine see well work compare antiemetic therapy alone prevent chemotherapy-induced nausea vomit patient cancer receive highly emetogenic ( cause vomit ) chemotherapy . Antiemetic drug , palonosetron hydrochloride , ondansetron , granisetron hydrochloride , may help lessen prevent nausea vomit patient treated chemotherapy . Olanzapine may help prevent chemotherapy-induced nausea vomit block brain receptor appear involve nausea vomiting .</brief_summary>
	<brief_title>Antiemetic Therapy With Without Olanzapine Preventing Chemotherapy-Induced Nausea Vomiting Patients With Cancer Receiving Highly Emetogenic Chemotherapy</brief_title>
	<detailed_description>Patients cancer may receive chemotherapy may cause nausea vomit . The purpose study determine use olanzapine combination antiemetic therapy significantly reduce nausea vomit large number patient receive chemotherapy . Patients randomize one two treatment arm . Please see `` Arms Intervention '' section detail information . The primary objective compare number patient nausea acute ( 0-24 hour post-chemotherapy ) , delay ( 24-120 hour post-chemotherapy ) overall period ( 0-120 hour post-chemotherapy ) patient receive HEC . The secondary objective : 1 . To compare complete response ( CR ) ( emetic episode use rescue medication ) acute , delay overall period 2 . To compare incidence potential toxicity ascribe olanzapine Protocol treatment begin ≤ 14 day registration . Patients receive treatment Days 1-4 . Patients permit take rescue therapy treat investigator 's choice nausea and/or emesis/retching , base clinical circumstance . After complete treatment , patient monitor side effect .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Diagnosis malignant disease No prior chemotherapy schedule receive HEC ( either cisplatincontaining regimen anthracycline + cyclophosphamide [ AC ] ) Cisplatin dose ≥70mg/m^2 , without chemotherapy agent ( ) OR Anthracycline ( 60 mg/m^2 ) plus cyclophosphamide ( 600 mg/m^2 ) Age ≥18 year Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 2 Required Initial Laboratory Values ≤ 120 day prior registration Serum Creatinine ≤2.0 mg/dL Serum glutamic oxaloacetic transaminase ( SGOT ) Serum glutamic oxaloacetic transaminase ( SGPT ) ≤3 x Upper Limit Normal ( ULN ) Absolute neutrophil count ( ANC ) ≥1500/mm^3 No nausea vomit ≤ 24 hour prior registration Negative pregnancy test ( serum urine ) do ≤7 day prior registration , woman childbearing potential ( per clinician discretion ) No severe cognitive compromise No known history CNS disease ( e.g . brain metastasis , seizure disorder ) No treatment another antipsychotic agent risperidone , quetiapine , clozapine , phenothiazine butyrophenone ≤30 day prior registration plan protocol therapy No chronic phenothiazine administration antipsychotic agent ( patient may receive prochlorperazine phenothiazine rescue antiemetic therapy ) No concurrent use amifostine No concurrent abdominal radiotherapy No concurrent use quinolone antibiotic therapy No chronic alcoholism ( determined investigator ) No know hypersensitivity olanzapine No known cardiac arrhythmia , uncontrolled congestive heart failure acute myocardial infarction within previous six month . No history uncontrolled diabetes mellitus ( e.g . insulin oral hypoglycemic agent )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>